Journal of Nuclear Medicine | |
Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial | |
Alberto Pupi1  David Antoniucci1  Renato Valenti1  Guido Parodi1  Gentian Memisha1  Roberto Sciagrà1  Giovanni Maria Santoro1  Angela Migliorini1  Guia Moschi1  | |
关键词: acute myocardial infarction; angioplasty; gated SPECT; stenting; | |
DOI : | |
学科分类:医学(综合) | |
来源: Society of Nuclear Medicine | |
【 摘 要 】
We used gated SPECT to evaluate the impact of abciximab on the efficacy of myocardial reperfusion in patients with acute myocardial infarction undergoing infarct-related artery stenting. Methods: The Abciximab and Carbostent Evaluation (ACE) trial randomized 400 infarct patients to stenting alone or stenting plus abciximab. One-month 99mTc-sestamibi gated SPECT was planned in a subgroup of consecutive patients to evaluate infarct size, infarct severity, left ventricular volumes, and ejection fraction. Results: The final study population included 182 patients (99 randomized to abciximab and 83 to stenting alone). Gated SPECT revealed smaller infarcts in the abciximab group than in the stenting-alone group (14.3% ± 11.7% vs. 18.1% ± 13%, P < 0.02), and lower infarct severity (minimum-to-maximum count ratio = 0.47 ± 0.17 vs. 0.41 ± 0.15, P < 0.02), resulting in a smaller left ventricular end-diastolic volume index (57.8 ± 20.0 vs. 64.6 ± 20.8 mL/m2, P = 0.03) and left ventricular end-systolic volume index (31.7 ± 17.4 vs. 37.5 ± 18.6 mL/m2, P = 0.05) in the abciximab group. One-month left ventricular ejection fraction was significantly higher in patients randomized to abciximab (47.4% ± 11.3% vs. 43.9% ± 11.7%, P = 0.05). Conclusion: The use of abciximab therapy as an adjunct to infarct-related artery stenting leads to a reduction in infarct size and severity, resulting in smaller 1-mo left ventricular volumes and better left ventricular function. Gated SPECT appears to be an ideal tool for outcome assessment in infarct patients undergoing different treatment strategies.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912010196282ZK.pdf | 566KB | download |